Project Grant R21DE032503

Award Date 8/1/23
Completion Date 7/31/26
Dollars Obligated $847K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
This $672,394.58 project grant from the National Institutes of Health's National Institute of Dental and Craniofacial Research Oral Diseases and Disorders Research program (CFDA 93.121) supports the development of a crosslinkable tissue particle implant for regenerating craniofacial bone. Led by Leefa Biotech LLC, the one-year award aims to demonstrate improved bone regeneration in critical-size cranial bone defects using the implant compared to the current standard of care. If successful, the...
This Project Grant award of $1,722,291.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund the development of novel metformin-releasing injectable scaffolds to enhance dental pulp stem cell-based regeneration of critical-sized craniofacial bone defects. The University of Maryland, Baltimore is the prime awardee. The key objectives are to: (1) demonstrate that metformin's osteogenic and...
The federal Project Grant award R03TR004613, funded by the National Center for Advancing Translational Sciences (NCATS - CFDA 93.350), aims to develop novel multiscale bone scaffolds using inorganic polymer materials for bone tissue regenerative engineering. The $141,478 award to North Carolina State University will fund research to optimize the synthesis of biocompatible inorganic polymer-based scaffolds, explore the mechanisms of cell attachment and migration, and investigate the ability of...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,963,287 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to Cleveland State University to develop a multi-functional, 3D printed dental implant that can effectively prevent peri-implantitis, a common and challenging implant-related oral infection. The project aims to engineer a silver-doped, antibacterial and bioactive composite material called "Ultra-PEEK" that can be 3D printed into...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded a $613,736 Project Grant to Cayman Chemical Co Inc. to develop novel osteogenic small-molecule pharmacotherapies for local delivery that stimulate alveolar bone regeneration. The goal is to address the clinical need for improved treatments for periodontitis-related bone resorption, especially in aging populations. The project leverages Cayman...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,029,497 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Oridivus LLC located in Decatur, Georgia. The purpose of this grant is to compare the efficacy of FTY720 nanofibers versus platelet-rich plasma (PRP) in improving oral wound healing in rodent and porcine animal models. The goal is to develop an immunoregenerative approach to enhance oral wound healing, which is a significant...
This Project Grant award of $312,871, awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel pro-angiogenic bone coating hydrogel (ABC hydrogel) for the treatment of osteonecrosis. The key objectives are to: 1) determine the physical, chemical, and cytocompatibility properties of the ABC hydrogel; 2) optimize the pro-angiogenic...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $685,594 to The Pennsylvania State University (Penn State) from June 16, 2025 through May 31, 2030. The project aims to develop advanced surgical and engineering approaches to enhance vascularization and oriented microvascular ingrowth for tissue-engineered bone grafts to improve outcomes in craniomaxillofacial...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $164,255 to East Carolina University to develop and evaluate novel dental materials with the ability to inhibit microbial biofilm formation while preserving beneficial oral bacteria. The key objectives are to: 1) synthesize a 2-aminoimidazole derivative, H10, and generate a new methacrylate-based antimicrobial...
This federal Project Grant award, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to investigate the mechanisms behind varied success of bone morphogenetic protein-2 (BMP-2) in palatal versus mandibular bone repair. The $129,420 award to The Leland Stanford Junior University, which runs from March 2025 to February 2027, focuses on two key objectives: 1) identifying how BMP-2-based palatal...

DETERMINING THE EFFICACY OF A NOVEL APATITE-BASED ANTIMICROBIAL BONE SCAFFOLD FOR CRANIOFACIAL SURGICAL APPLICATIONS - PROJECT ABSTRACT / SUMMARY TRAUMATIC MUSCULOSKELETAL INJURIES COMMONLY INVOLVE MASSIVE BONE AND SOFT TISSUE DISRUPTIONS, WITH SUBSEQUENT INFECTION POSSIBLY DEVELOPING AS A FREQUENT COMPLICATION. THIS LEADS TO MULTIPLE SURGICAL DEBRIDEMENTS, WHICH FURTHER INCREASES THE SIZE OF THE DEFECT. SURGICAL DEBRIDEMENT IS NEEDED TO ACHIEVE A CLEAN WOUND REQUIRED FOR SUCCESSFUL BONY RECONSTRUCTION. THUS, ADDRESSING CRITICAL-SIZE BONE DEFECTS- WHICH CANNOT BE HEALED WITHOUT REPLACING THE LOST BONE WITH BONE GRAFT MATERIALS-IS OFTEN DELAYED UNTIL WOUND HOMEOSTASIS IS OBTAINED. SUCH DELAY MAY LEAD TO SECONDARY COMPLICATIONS AND LIFE-LONG DISABILITY. SELF-SOURCED OR AUTOGRAFT BONE IS THE "GOLD STANDARD" AMONG ALL GRAFT MATERIALS, BUT THE AMOUNT OF BONE SITES AVAILABLE IS LIMITED. THIS PRODUCES INSUFFICIENT GRAFT MATERIAL TO FILL CRITICAL-SIZE DEFECTS, AND SUCH HARVEST REQUIRES SECONDARY SURGICAL SITES. DECELLULARIZED AND STERILIZED CADAVERIC OR ALLOGRAFT BONE COMMONLY FAILS IN BACTERIALLY CONTAMINATED WOUND ENVIRONMENTS. ENGINEERED BONE SUBSTITUTES MAY PROVIDE A SOLUTION TO THIS DILEMMA IF THE CURRENT LIMITATIONS OF THESE MATERIALS CAN BE ADDRESSED, INCLUDING THEIR INABILITY TO MATCH THE MECHANICAL STRENGTH, POROSITY, AND BIOACTIVITY OF AUTOGRAFTS. IDEALLY, SUCH ENGINEERED BONE SCAFFOLDING MATERIALS SHOULD ALSO POSSESS ANTIMICROBIAL PROPERTIES. IN THE PAST, SCAFFOLD SURFACES HAVE BEEN COATED WITH ANTIMICROBIAL/BROAD-SPECTRUM ANTIBIOTICS, BUT THE RAPID RELEASE OR "BURST EFFECT" OF THESE COATINGS ONLY PROVIDES SHORT-TERM PROTECTION, AND SUDDEN HIGH ANTIBIOTIC LEVELS CAN BE TOXIC TO THE LOCAL CELLS NEEDED FOR HEALING. ONE OTHER OPTION COULD BE TO TAILOR BONE SCAFFOLDS WITH INTRINSIC ANTIMICROBIAL SURFACE PROPERTIES. THE BONE MATRIX CRYSTALLINE HYDROXYAPATITE (HA) IS KNOWN FOR ITS BIOCOMPATIBILITY, OSTEOGENIC PROPERTIES, AND BIO-ABSORBABILITY BUT LACKS MECHANICAL STRENGTH AND CONTROLLABLE RESORPTION PROPERTIES. TO IMPROVE THE MECHANICAL PROPERTIES OF HA, WE HAVE USED BOTH IONIC CHEMICAL SUBSTITUTION AND VARIATION IN TEMPERATURES TO SYNTHESIZE VARIOUS APATITE TYPES. OUR PRELIMINARY DATA REVEALED THAT FLUORIDE SUBSTITUTED APATITE (FLUORAPATITE (FA)), WHEN SINTERED ABOVE 11500C, PRODUCED IMPROVED MECHANICAL STRENGTHS, INCLUDING COMPRESSION STRENGTHS AND INCREASED BONE DEPOSITION IN AN IN VIVO MODEL. WE HAVE ALSO SHOWN THAT WHEN KNOWN ANTIMICROBIAL METALS ARE CO-DEPOSITED AND IMMOBILIZED WITHIN THE APATITE CRYSTALS DURING THE SYNTHESIS OF FA, SOME COMBINATION OF APATITES EXHIBITED IMPROVED ANTIMICROBIAL PROPERTIES WITHOUT PRODUCING CELL CYTOTOXICITY. THIS PROPOSAL IS DESIGNED TO TEST ONE SUCH APATITE, ZINC-DOPED FLUORAPATITE (ZN-FA). BASED ON OUR PRELIMINARY DATA, IT WAS HYPOTHESIZED THAT AN OPTIMIZED MOLAR PERCENT ZINC SUBSTITUTED POROUS FLUORAPATITE SCAFFOLDS WOULD HAVE THE POTENTIAL TO REGENERATE BONE TISSUE WITHIN BOTH STERILE AND INFECTED SITES. THIS HYPOTHESIS WILL BE TESTED USING THREE SPECIFIC AIMS. SPECIFIC AIM 1 IS DESIGNED TO FABRICATE AND TEST BOTH MECHANICAL AND ANTIMICROBIAL IN VITRO PROPERTIES OF VARIOUS MOLAR PERCENT ZN SUBSTITUTED FA, SPECIFIC AIMS 2 AND 3 WILL TEST THE EFFICACY OF AN OPTIMIZED MOLAR PERCENT ZINC SUBSTITUTED FA TO GENERATE BONE TISSUES IN CONTAMINATED AND CRITICAL-SIZE POCKETS, RESPECTIVELY.

Posted 8/1/23, 12:00 AM